FREMONT, Calif.--(BUSINESS WIRE)--ARYx Therapeutics, Inc. (NASDAQ:ARYX) today regretfully announced it will not be able to present at the Jefferies 2nd Annual Healthcare Conference in New York City on June 25, 2008. The company is working with its partner Procter & Gamble Pharmaceuticals (P&G) to finalize their analyses and reach a mutual conclusion about the results of a Thorough QT (TQT) study of ATI-7505, a prokinetic agent in Phase 2 clinical development. It is expected this work will be concluded within the next two weeks and, until that time, ARYx will not be in a position to disclose any other details about the TQT study or the ATI-7505 program. ARYx welcomes questions about any of its other products in development.
